Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix in Adult Subjects With Irritable Bowel Syndrome (IBS) Subtypes IBS-C and IBS-D

Trial Profile

A Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix in Adult Subjects With Irritable Bowel Syndrome (IBS) Subtypes IBS-C and IBS-D

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Blautix (Primary)
  • Indications Irritable bowel syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors 4D Pharma PLC
  • Most Recent Events

    • 24 Oct 2018 Status changed from planning to recruiting.
    • 15 Jun 2018 New trial record
    • 08 May 2018 According to the 4D Pharma PLC media release, the U.S. Food and Drug Administration (FDA) has cleared, an Investigational New Drug Application for Blautix for the treatment of Irritable Bowel Syndrome .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top